Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02584608 · ClinicalTrials.gov registry record · Phase 2
Use of ACTIMMUNE in Patients With ADO2
A Phase 2 study of Autosomal Dominant Osteopetrosis Type 2, sponsored by Indiana University.
- Completed
- Registry status
- Phase 2
- Development phase
- 12
- Enrollment target
- 1
- Study location
NCT02584608: Completed Phase 2 study of Autosomal Dominant Osteopetrosis Type 2, sponsored by Indiana University.
NCT02584608 is a Phase 2 study of Autosomal Dominant Osteopetrosis Type 2 that has completed, run by Indiana University. The registered enrollment target is 12 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02584608, a Phase 2 study of Autosomal Dominant Osteopetrosis Type 2, has completed, sponsored by Indiana University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 12 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is an open label use of ACTIMMUNE for patients with Autosomal Dominant Osteopetrosis Type 2(ADO2). Effects of treatment will be evaluated after 14 weeks on ACTIMMUNE by bone resorption markers. This study will treat 12 patients with ADO2 recruited from Indiana University and Riley Hospital for Children at Indiana University Health.
Primary Outcome
Evaluate for changes in bone resorption markers including CTX, NTX/creatinine ratio between baseline and 14 weeks
Conditions Studied
Interventions
- DRUG ACTIMMUNE
Study Locations (1)
Indiana
- Indiana University School of Medicine - Indianapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2016-01-01 |
| Est. Completion | 2019-11-12 |
| Phase | Phase 2 |
What the finished NCT02584608 record still lists
NCT02584608 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 12 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (91% lower).
The record links to 1 condition, with Autosomal Dominant Osteopetrosis Type 2 appearing as the primary indexed condition, and to 1 intervention - of which ACTIMMUNE is the first listed.
NCT02584608 reports a single indexed study location in Indiana.
Frequently Asked Questions
What is clinical trial NCT02584608 about?
NCT02584608 is a clinical study titled "Use of ACTIMMUNE in Patients With ADO2". This study is an open label use of ACTIMMUNE for patients with Autosomal Dominant Osteopetrosis Type 2(ADO2). Effects of treatment will be evaluated after 14 weeks on ACTIMMUNE by bone resorption markers. This study will treat 12 patients with ADO2 recruited from Indiana University and Riley Hospita...
What is the current status of trial NCT02584608?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 12 participants. The study started on 2016-01-01. Estimated completion is 2019-11-12.
What conditions does trial NCT02584608 study?
This clinical trial studies the following conditions: Autosomal Dominant Osteopetrosis Type 2.
What interventions are being tested in trial NCT02584608?
The interventions under investigation include: ACTIMMUNE (DRUG).
Who is sponsoring clinical trial NCT02584608?
This trial is sponsored by Indiana University, which has 890 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02584608 being conducted?
This trial has 1 study location across Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02584608's enrollment target sits among peer trials
12 1948th of 2000 higher than 34 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02602769 · 12 participants
Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome
- NCT02605421 · 12 participants · Phase 2
Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma
- NCT02619448 · 12 participants · Early Phase 1
Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC
- NCT03311503 · 12 participants · Phase 1
Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI